Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats

Isao Date, T. Shingo, H. Yoshida, K. Fujiwara, K. Kobayashi, A. Takeuchi, T. Ohmoto

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

In order to deliver glial cell line-derived neurotrophic factor (GDNF) into the brain, we have established a cell line that produces GDNF in a continuous fashion by genetic engineering. These cells were encapsulated and grafted into parkinsonian model rats that had received unilateral intrastriatal injection of 6-hydroxydopamine 2 weeks earlier. Neurochemical analysis showed that GDNF has been produced from the capsule for 6 months after grafting and histological analysis revealed good survival of GDNF-producing cells in the capsule 6 months after grafting. The density of nigrostriatal dopaminergic fibers in the striatum as well as the number of dopaminergic cell bodies in the substantia nigra recovered significantly after GDNF-producing cell grafting. These results suggest the possible application of GDNF-producing cell grafting for the treatment of Parkinson's disease.

Original languageEnglish
Pages (from-to)397-401
Number of pages5
JournalCell Transplantation
Volume10
Issue number4-5
Publication statusPublished - 2001

Fingerprint

Glial Cell Line-Derived Neurotrophic Factor
Rats
Cells
Capsules
Genetic engineering
Genetic Engineering
Oxidopamine
Substantia Nigra
Parkinson Disease
Neuroglia
Nerve Growth Factors
Brain
Cell Line
Injections
Fibers

Keywords

  • Encapsulation
  • Glial cell line-derived neurotrophic factor GDNF)
  • Neural transplantation
  • Parkinson's disease

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation

Cite this

Date, I., Shingo, T., Yoshida, H., Fujiwara, K., Kobayashi, K., Takeuchi, A., & Ohmoto, T. (2001). Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. Cell Transplantation, 10(4-5), 397-401.

Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. / Date, Isao; Shingo, T.; Yoshida, H.; Fujiwara, K.; Kobayashi, K.; Takeuchi, A.; Ohmoto, T.

In: Cell Transplantation, Vol. 10, No. 4-5, 2001, p. 397-401.

Research output: Contribution to journalArticle

Date, I, Shingo, T, Yoshida, H, Fujiwara, K, Kobayashi, K, Takeuchi, A & Ohmoto, T 2001, 'Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats', Cell Transplantation, vol. 10, no. 4-5, pp. 397-401.
Date, Isao ; Shingo, T. ; Yoshida, H. ; Fujiwara, K. ; Kobayashi, K. ; Takeuchi, A. ; Ohmoto, T. / Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. In: Cell Transplantation. 2001 ; Vol. 10, No. 4-5. pp. 397-401.
@article{bc526cc9e5a24c08b5a6903c03c467c4,
title = "Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats",
abstract = "In order to deliver glial cell line-derived neurotrophic factor (GDNF) into the brain, we have established a cell line that produces GDNF in a continuous fashion by genetic engineering. These cells were encapsulated and grafted into parkinsonian model rats that had received unilateral intrastriatal injection of 6-hydroxydopamine 2 weeks earlier. Neurochemical analysis showed that GDNF has been produced from the capsule for 6 months after grafting and histological analysis revealed good survival of GDNF-producing cells in the capsule 6 months after grafting. The density of nigrostriatal dopaminergic fibers in the striatum as well as the number of dopaminergic cell bodies in the substantia nigra recovered significantly after GDNF-producing cell grafting. These results suggest the possible application of GDNF-producing cell grafting for the treatment of Parkinson's disease.",
keywords = "Encapsulation, Glial cell line-derived neurotrophic factor GDNF), Neural transplantation, Parkinson's disease",
author = "Isao Date and T. Shingo and H. Yoshida and K. Fujiwara and K. Kobayashi and A. Takeuchi and T. Ohmoto",
year = "2001",
language = "English",
volume = "10",
pages = "397--401",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "4-5",

}

TY - JOUR

T1 - Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats

AU - Date, Isao

AU - Shingo, T.

AU - Yoshida, H.

AU - Fujiwara, K.

AU - Kobayashi, K.

AU - Takeuchi, A.

AU - Ohmoto, T.

PY - 2001

Y1 - 2001

N2 - In order to deliver glial cell line-derived neurotrophic factor (GDNF) into the brain, we have established a cell line that produces GDNF in a continuous fashion by genetic engineering. These cells were encapsulated and grafted into parkinsonian model rats that had received unilateral intrastriatal injection of 6-hydroxydopamine 2 weeks earlier. Neurochemical analysis showed that GDNF has been produced from the capsule for 6 months after grafting and histological analysis revealed good survival of GDNF-producing cells in the capsule 6 months after grafting. The density of nigrostriatal dopaminergic fibers in the striatum as well as the number of dopaminergic cell bodies in the substantia nigra recovered significantly after GDNF-producing cell grafting. These results suggest the possible application of GDNF-producing cell grafting for the treatment of Parkinson's disease.

AB - In order to deliver glial cell line-derived neurotrophic factor (GDNF) into the brain, we have established a cell line that produces GDNF in a continuous fashion by genetic engineering. These cells were encapsulated and grafted into parkinsonian model rats that had received unilateral intrastriatal injection of 6-hydroxydopamine 2 weeks earlier. Neurochemical analysis showed that GDNF has been produced from the capsule for 6 months after grafting and histological analysis revealed good survival of GDNF-producing cells in the capsule 6 months after grafting. The density of nigrostriatal dopaminergic fibers in the striatum as well as the number of dopaminergic cell bodies in the substantia nigra recovered significantly after GDNF-producing cell grafting. These results suggest the possible application of GDNF-producing cell grafting for the treatment of Parkinson's disease.

KW - Encapsulation

KW - Glial cell line-derived neurotrophic factor GDNF)

KW - Neural transplantation

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0034874180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034874180&partnerID=8YFLogxK

M3 - Article

C2 - 11549061

AN - SCOPUS:0034874180

VL - 10

SP - 397

EP - 401

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 4-5

ER -